LENZ Therapeutics Investor Relations Material
Latest events
Study Update
LENZ Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from LENZ Therapeutics Inc
Access all reports
LENZ Therapeutics Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative ophthalmic therapies aimed at improving vision. The company's primary focus is on treating presbyopia, a common age-related condition that affects near vision. LENZ Therapeutics is currently advancing its lead product candidates, LNZ100 and LNZ101, which are in Phase III clinical trials. These products are aceclidine-based eye drops designed to restore near vision for individuals with presbyopia. The company is headquartered in Del Mar, California, and its shares are listed on the NASDAQ.
Key slides for LENZ Therapeutics Inc
Q4 2024
LENZ Therapeutics Inc
Q4 2024
LENZ Therapeutics Inc
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
LENZ
Country
🇺🇸 United States